ASDERA is developing the first drug with the potential to change the course of neuro-degenerative diseases, including Alzheimer's, Parkinson's and Huntington's disease as well as amyotrophic lateral sclerosis (ALS).
There are currently no drugs with a lasting effect for people with
AD, PD, HD, or ALS. ASD-005 (pat. pend.) addresses the mechanism underlying "deranged" endocytosis and a drug to "rerange" it.
The proposed mechanism of action is down-regulation of endocytosis to restore the capacity of lysosomes to fuse with autophagosomes by preventing lysosomes from inhibiting autophagy (via MTORC1). The proposed oral drug is a derivative of HP-α-cyclodextrin that down-regulates the activity of the PI-cycle, which controls endocytosis.
(click on either of the icons in the lower left corner to download a 2-page flyer pdf (left) or a pdf deck (right) with more details)